SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from…

• BA
  Bill and Melinda Gates Foundation

  Award: INV-016202
• OF
  Oak Foundation
• WT
  Wellcome Trust

  Awards: 203141/Z/16/Z, 101122/Z/13/Z, 090532/Z/09/Z
• UR
  UK Research and Innovation
• CF
  Coalition for Epidemic Preparedness Innovations
• NI
  National Institute for Health and Care Research

  Awards: 63/125,984, PCT/GB2012/000467, 277,546
• DO
  Department of Health and Social Care
• PH
  Public Health England
• CA
  Chinese Academy of Meteorological Sciences

  Award: 2018-I2M-2-002
• CN
  Conselho Nacional de Desenvolvimento Científico e Tecnológico

  Award: 403276/2020-9
• IS
  Israel Science Foundation

  Award: 3814/19
• FD
  Fundação de Amparo à Pesquisa do Estado do Amazonas
• CA
  Chinese Academy of Medical Sciences

  Award: 2018-I2M-2-002
• FO
  Fundação Oswaldo Cruz

  Award: VPPCB-007- FIO-18-2-30
• NI
  National Institutes of Health

  Award: U19 I082360
• MR
  Medical Research Council

  Awards: MC_PC_19059, MR/N00065X/1, MR/V001329/1, MR/S020039/1, MR/P011705/1, MR/P011705/2
• BA
  Biotechnology and Biological Sciences Research Council

  Awards: BBS/E/D/20002173, BBS/E/D/30002277, BBS/E/D/20002174
• NO
  NIHR Oxford Biomedical Research Centre